Coastlands Capital reports acquisition of $319,000 in Bolt Biotherapeutics common shares
BOLT•Coastlands Capital, a 10% owner of Bolt Biotherapeutics, purchased 50,000 common shares at $6.38 each, raising its indirect beneficial ownership to 462,416 shares.
1. Share purchase
Coastlands Capital purchased 50,000 Bolt Biotherapeutics common shares at $6.38 per share. Its indirect beneficial ownership rose to 462,416 common shares after the purchase.
